Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Tfh determinants for effective responses to influenza vaccination in older individuals

Project description

Modelling vaccine immunity in older adults

Seasonal influenza causes significant health issues for older adults, as vaccines often provide insufficient protection in this age group. The EU-funded TEaR-flu project will investigate why some older individuals develop stronger immunity than others by studying specialised T follicular helper cells. Using single-cell genomics and sequencing from a clinical cohort, researchers will compare high and low vaccine responders to identify key molecular differences. These findings will be validated through computational analysis and human organoid models. By integrating clinical data, the project aims to create predictive models of vaccine effectiveness. TEaR-flu’s goal is to ultimately identify new targets to improve vaccine efficacy and develop better immunisation strategies for vulnerable populations.

Objective

Seasonal influenza causes significant morbidity and mortality each year, especially among older adults. This is due to reduced vaccine efficacy in this group. Indeed, despite vaccination efforts, many individuals in this age range remain unprotected, highlighting the urgent need to identify factors that influence effective immune responses. This project, TEaR-flu, focuses on antigen-specific T follicular helper (Tfh) cells, the specialised T cell subset that provides help to B cells, to uncover molecular and cellular features that differentiate older individuals who mount strong (high responders, HR) from those who mount weak (low responders, LR) responses to influenza vaccination.

Leveraging a large clinical cohort (~300 older individuals) that will be collected before the start of this proposal, I will stratify participants based on serological responses and perform single-cell transcriptomics and TCR repertoire sequencing on influenza-specific T cells from 40 selected HR and LR individuals. Using computational analyses, I will then identify transcriptional programs and TCR motifs that differ between HR and LR and, consequently, are linked to vaccine immunogenicity. Findings will be validated in silico, using publicly available datasets, and functionally tested in human tonsil organoids, providing mechanistic insights into the drivers of vaccine responsiveness. Finally, a model for vaccine immunogenicity will be developed, considering not only the transcriptional differences but also clinical data from the cohort volunteers.

All together, TEaR-flu is a highly interdisciplinary proposal that combines immunology, single-cell genomics, computational biology, and organoid models to generate predictive models of vaccine immunogenicity and identify potential targets for improved vaccine efficacy and new vaccine strategies.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-WIDERA-2025-TALENTS-01

See all projects funded under this call

Coordinator

FUNDACAO GIMM - GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINE
Net EU contribution
€ 207 183,12
Address
AVENIDA PROFESSOR EGAS MONIZ
1649-035 LISBOA
Portugal
Activity type
Research Organisations
Links
Total cost
No data